Garry Nicholson

Garry Nicholson   |   Director

Mr. Nicholson currently serves as chairman of the board for G1 Therapeutics and as a board member for Turning Point Therapeutics, Five Prime Therapeutics, Personal Genome Diagnostics and Tmunity Therapeutics. He previously served on the TESARO board prior to its acquisition by GlaxoSmithKline and as president and CEO of XTuit Pharmaceuticals. Prior to that, he was President of Pfizer Oncology, where he oversaw global commercialization and sales, clinical development, regulatory and business strategies. He has also held various leadership positions in the oncology division of Eli Lilly and Company. Mr. Nicholson holds an M.B.A. from the University of South Carolina and a B.S. in Pharmacy from the University of North Carolina at Chapel Hill. • David Kabakoff, Ph.D.
Chairman
• Michael Richman
Director
• Elaine V. Jones, Ph.D.
Director
• Chau Q. Khuong
Director
• Judith J. Li
Director
• Briggs Morrison, M.D.
Director
• Garry Nicholson
Director
• Stephen Webster
Director
• Stella Xu, Ph.D.
Director